baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

LONZA N/ CH0013841017 /

08/01/2025 17:30:06	Chg. +3.40	Volume	Bid21:41:33	Ask21:41:33	Market Capitalization	Dividend Y.	P/E Ratio
557.60CHF	+0.61%	141,090 Turnover: 78.48 mill.	-Bid Size: 118	-Ask Size: 50	41.52 bill.CHF	0.72%	62.79

GlobeNewswire 26/08/2024 Simtra BioPharma Solutions Appoints Dr. Lidia Serina as Head of Development Sciences

GlobeNewswire 23/08/2024 Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, G...

GlobeNewswire 08/08/2024 Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 06/08/2024 Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 14/06/2024 Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at...

GlobeNewswire 13/06/2024 Repligen Announces CEO Transition Plan

GlobeNewswire 30/05/2024 Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively licens...

GlobeNewswire 15/05/2024 Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ dec...

GlobeNewswire 08/05/2024 Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 08/05/2024 Maravai LifeSciences Reports First Quarter 2024 Financial Results

GlobeNewswire 04/04/2024 Galapagos showcases innovative approach in hematological cancer care with clinical and translational...

GlobeNewswire 04/04/2024 Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’...

GlobeNewswire 27/02/2024 Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire 15/02/2024 Galapagos presents at EBMT-EHA annual meeting 2024

GlobeNewswire 04/01/2024 Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further exp...

GlobeNewswire 19/12/2023 Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufacture...

GlobeNewswire 09/12/2023 Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 an...

GlobeNewswire 07/12/2023 Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at A...

GlobeNewswire 07/12/2023 Business Update

GlobeNewswire 06/11/2023 Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire 01/11/2023 Dr. Hartmut Tintrup joins Cellbox Solutions GmbH as new CEO

GlobeNewswire 19/10/2023 Viralgen welcomes back Andy Holt as CCO

GlobeNewswire 16/10/2023 Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumoc...

GlobeNewswire 02/10/2023 Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer

GlobeNewswire 20/09/2023 Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023

LONZA N/ CH0013841017 /

If you wish to receive reply to your feedback, please provide your email address.